FindTrial
Sign In

Safety and efficacy of a new renal denervation system for the treatment of hypertension

Safety and efficacy of a prospective, multicenter, randomized, parallel-controlled renal denervation system for the treatment of essential hypertension and renal hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017815
Enrollment
Unknown
Registered
2018-08-16
Start date
2018-09-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

RDN group:renal denervation
Control group:Sham group

Sponsors

Beijing Anzhen Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years old; 2. Mean office blood pressure(SBP) =150/90mmHg; or an average of 24 hours of systolic blood pressure(ASBP) = 135mmHg in hpertensive patients have taken 2 or more antihypertensive drugs for 4 weeks; Mean office systolic blood pressure(SBP) = 150mmHg; or an average of 24 hours of systolic blood pressure(ASBP) = 145mmHg after stopping hypertensive medications for 2 weeks or more; 3. Rest heart rate=70bpm.

Exclusion criteria

Exclusion criteria: 1. Pregnant women, lactating patients and patients planning to become pregnant; 2. Unilateral or bilateral renal artery anatomy; 3. History of previous renal artery interventional therapy.

Design outcomes

Primary

MeasureTime frame
Blood preesure;—

Countries

China

Contacts

Public ContactGenshan Ma

Zhongda Hospital, Southeast University

20941705@qq.com+86 025-83262400

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 22, 2026